Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the ...

A screen showing a city environment filled with multiple smartphones and tablets in various retail locations and displays.